⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 9, 2024Neurology

Ocrelizumab in Patients With Early-stage RRMS—Results from the Phase IIIb ENSEMBLE Trial and the Matched Real-world NTD MS Registry Cohort (P9-6.005)

Hans‐Peter Hartung Trygve Holmøy Jens Wuerfel Yanic Heer Stefan Braune Arnfin Bergmann Mel Zuercher Sabrina Guye Thomas Kuenzel Suzanne Moore Timothy R. Vollmer

View Full Paper

Ask AI

Bookmark

Share

Abstract

To contextualize ocrelizumab effectiveness in early-stage relapsing-remitting multiple sclerosis (RRMS) from the multicenter, open-label, single-arm, Phase IIIb ENSEMBLE trial (NCT03085810) with real-world, first-line disease-modifying therapies (DMTs), using the German NeuroTransData (NTD) MS registry

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hartung et al. (2024) studied this question.

synapsesocial.com/papers/68e6fdb8b6db643587678156 https://doi.org/10.1212/wnl.0000000000205641

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Low Disease Activity Over 4 Years of Ocrelizumab Therapy in Treatment-naive Patients with High-activity, Early-stage Relapsing-remitting Multiple Sclerosis in the ENSEMBLE Study (P10-6.007)2024
2ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial2024 · 7 citations
3Real-world Data on Ocrelizumab Treatment: Efficacy, Safety, and Tolerability Analysis in Patients with Relapsing Remitting and Primary Progressive Multiple Sclerosis in Southeastern Ontario (P2-6.014)2024
4A Retrospective, Single-Arm, Observational Study in Patients with Multiple Sclerosis in India Receiving Ocrelizumab Therapy for 1 YearHuman Clinical Trial · 2026
5Ocrelizumab in early relapsing–remitting multiple sclerosis: first interim analysis of the MUSPO Italian prospective cohortCohort Study · 2026